SPOTLIGHT: Isolagen reports mixed Phase III data

Isolagen has produced mixed results for two Phase III studies of treating contour deformities with the Isolagen Process. The Exton, Pennsylvania-based biotech said it hit three out of four primary endpoints. Researchers say they'll launch a new study in November that can be used to support a BLA application in 2006. Release

Suggested Articles

In this week's EuroBiotech Report, AstraZeneca plans 2020 lupus filing, Roche's SMA trial hits endpoint and Kiadis cuts staff in R&D pivot.

In our EuroBiotech roundup this week, NEC and Vaximm ink cancer vaccine pact, Compugen posts cancer data and Lunac raises cash.

Biotech venture fund ATAI Life Sciences has partnered with artificial intelligence drug discovery specialist Cyclica to form a new JV.